Skip to main content
. 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118

Figure 6.

Figure 6

Participants achieving seroresponse (95% CIs) 1 month after vaccination with XBB.1.5-adapted BNT162b2 30 μg (evaluable immunogenicity population). A ≥4-fold rise from before study vaccination in FFRNT 50% serum neutralizing titers was considered a seroresponse. For participants with a baseline measurement <LLOQ, a postvaccination assay result of ≥4 × LLOQ was considered a seroresponse. FFRNT = fluorescent focus reduction neutralization test; LLOQ = lower limit of quantitation.